Rifampicinによる肺結核治療成績

DOI Web Site PubMed

書誌事項

タイトル別名
  • CLINICAL EFFECTS OF RIFAMPICIN FOR PULMONARY TUBERCULOSIS PATIENTS
  • Rifampicin ニ ヨル ハイケッカク チリョウ セイセキ 2 ジュウショウ タザイ タイセイレイ ニ タイスル セイセキ
  • 2. Results of Rifampicin Treatment for Advanced Pulmonary Tuberculosis Patients Resistan t to Conventional Antituberculous Drugs
  • 第2報重症多剤耐性例に対する成績

この論文をさがす

説明

The therapeutic effects of Rifampicin RFP, on 31 re-treatment cases of chronic pulmonary tuberculosis with sclerotic walled cavities and drug resistance were investigated. All cases showed conIinuous pcsitive tubercle bacilli in sputum in spite of long term treatment with conventional primary and secondary antituberculous drugs. About 80 % of patients were classified as far advanced by NTA classification.<BR>RFP was used in combination wit previously unused drugs or less resistant drugs.450mg of RFP were given orally once daily before breakfast or in 3 divided dose after each meal for 6 months. The rate of sputum conversion was 35.5 %, 58.6 and 63.0% at 2, 4 and 6months. on smear and 45.2 %, 48.3%, and 57.1 % on culture, respectively. The better results were obtained by the combination of RFP, EB and INH.<BR>The improvement of chest X ray fndirgs was slight during 6 months treatment, as the majority of patients were of fibrocaseous or far advanced mixed type.<BR>Clinical signs and symptoms became, in general, slightly b e tter under RFP treatment. No serious side effects were observed except one patient who showeri high fever with diarrhea at 4 months. Incidence of resistant strains to RFP was higher in these cases than in the previous: reported original cases. No improvement of the disease was expected when the tubercle became resistant to 10 mcg/ml RFP.<BR>It is concluded that RFP is eective, to some extent, for the previously treated chronic pulmonary tuberculosis patients. especially when RFP is combined with other sensitive antituberculous drugs. for instance, etharnbutol.

収録刊行物

  • 結核

    結核 46 (11), 423-428, 1971

    一般社団法人 日本結核病学会

詳細情報 詳細情報について

問題の指摘

ページトップへ